VRTX · News · 20261106N
Regulatory Approval Milestones
VERTEX PHARMACEUTICALS INC / MA · 2026-11-06 · Importance 41 · Surprise 60 · In source text
The market report identifies FDA approval of Vertex’s CRISPR-enabled therapy Casgevy as a development in recombinant DNA technology. It does not provide the approval date, financial impact, or any related revenue or outlook estimate. No additional company-specific regulatory changes or commitments are reported.
Key facts
- The FDA approved Vertex Pharmaceuticals' CRISPR-enabled therapy, Casgevy. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The FDA approved Vertex Pharmaceuticals' CRISPR-enabled therapy, Casgevy. |